Redhill Biophrma ADR RDHL

$0.51 +0.01 (1.22%)

Valuation

Market cap
4,267,000
Revenue TTM
$290,000
Net income TTM
$-430,000
PE ratio
0.00
Forward PE
—
Profit margin
-148.28%
Debt to equity
0.00

Trading

Volume
125,163
Avg volume
2,628,392
Day's range
$0.46 – $0.52
Shares out
8,888,000
Stochastic %K
26%
Beta
4.91
Analysts
Strong Buy
Price target
$40.00

Price

Company profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hos...

Show more

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; Rebyota, a microbiota-based therapy for prevention of recurrent Clostridioides difficile infection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. It also commercializes Clenpiq, a ready-to-drink low-volume bowel preparation. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
972 3 541 3131
Website
https://www.redhillbio.com
Address
21 Ha’arba’a Street, Tel Aviv-Yafo, Israel

Latest news

Stocktwits

Zaksab Oct 20, 7:24 PM
$RDHL Should I back Zuckerberg, Musk or Ben-Asher? All cost me the same in terms of transaction fee…
0 replies
yoni30 Oct 19, 7:41 PM
$RDHL Something very strange: Even after a positive announcement that it is receiving money, the stock isn't rising enough.
2 replies
athebeast Oct 19, 12:54 PM
$PLAG $RDHL $DKI $MASK.X You shouldn't put $PLAG on there as it's literally about to be negative
0 replies
LivelearnGrow Oct 19, 12:11 PM
Massive breakout starting on ticker UPLD. If you want to catch the next monster runners, keep UPLD on watch. UPLD just sitting at 2M float, double digit potential. $PLAG $RDHL $DKI $MASK.X :))
0 replies
Stock_Catcher Oct 19, 12:00 PM
$RDHL $2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma
0 replies
yoni30 Oct 14, 2:15 PM
$RDHL What’s going to happen with the drop in share price? This company couldn't care less about its shareholders; the question is whether there's any chance of breaking past the $1 mark.
1 replies
Nuisance Oct 13, 2:42 PM
$RDHL 📈🙏
0 replies
yoni30 Oct 13, 2:04 PM
$RDHL What about transparency? What about business progress or updates? Why aren't there updates on sales—if any—of the new products? As long as the situation remains this way, extending the 180-day period won't help.
3 replies